Skip to main content
. 2026 Jan 1;16(6):2952–2983. doi: 10.7150/thno.124189

Figure 7.

Figure 7

In vivo biodistribution and histological evaluation of MCT-NE#9. (A-D) Plasma and tissue distribution of ATV and DTX in 4T1 tumor-bearing mice after IV administration of MTD (ATV 2.5 mg/kg + DTX 10 mg/kg, once every 3 weeks) and once-daily oral administration of MCT-NE#9 (ATV 2.5 mg/kg + DTX 10 mg/kg) for 21 days. (E) Representative hematoxylin and eosin (H&E)-stained sections of heart, lungs, liver, intestine, spleen, and kidneys from control, MTD (IV), and MCT-NE#9 (Oral) groups after 4 weeks of repeated administration. Scale bar: 100 µm.